{"name":"Aegerion Pharmaceuticals, Inc.","slug":"aegerion-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"AEGR-733 and ezetimibe","genericName":"AEGR-733 and ezetimibe","slug":"aegr-733-and-ezetimibe","indication":"Other","status":"phase_2"},{"name":"AEGR-733","genericName":"AEGR-733","slug":"aegr-733","indication":"Familial chylomicronemia syndrome (Type I hyperlipoproteinemia)","status":"phase_3"},{"name":"AEGR-733 and fenofibrate","genericName":"AEGR-733 and fenofibrate","slug":"aegr-733-and-fenofibrate","indication":"Severe hypertriglyceridemia","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AEGR-733 and atorvastatin","genericName":"AEGR-733 and atorvastatin","slug":"aegr-733-and-atorvastatin","indication":"Hypercholesterolemia","status":"phase_2"}]}],"pipeline":[{"name":"AEGR-733 and ezetimibe","genericName":"AEGR-733 and ezetimibe","slug":"aegr-733-and-ezetimibe","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AEGR-733","genericName":"AEGR-733","slug":"aegr-733","phase":"phase_3","mechanism":"AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor that reduces the production and secretion of apolipoprotein B-containing lipoproteins.","indications":["Familial chylomicronemia syndrome (Type I hyperlipoproteinemia)","Severe hypertriglyceridemia"],"catalyst":""},{"name":"AEGR-733 and atorvastatin","genericName":"AEGR-733 and atorvastatin","slug":"aegr-733-and-atorvastatin","phase":"phase_2","mechanism":"AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor, and atorvastatin is a HMG-CoA reductase inhibitor.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"AEGR-733 and fenofibrate","genericName":"AEGR-733 and fenofibrate","slug":"aegr-733-and-fenofibrate","phase":"phase_2","mechanism":"AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor combined with fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, to reduce triglycerides and apolipoprotein B-containing lipoproteins.","indications":["Severe hypertriglyceridemia","Familial chylomicronemia syndrome"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNVU1ITE5oUElHaHlIWHFGQnl0MWxhR2lnR1A1OXNpNEJ6MzR6S1pQSC1wT0Q0ZjJGM1oxazhTcnNQM21xcTZ0MlpndGQwU1UtMjF1OXlwaXZsaVpRczAxd0JPV3pKeko3R3FXWk0tTGg5anpFMTVFMUFQY1ZiZWFsRlBrck5ZaW4tUV93UlVIc0ltd0xuUlBpMlBlWDJkbTRRMGNCZ0VabUtUTkxYV2cxVVBkX0FxYjJ0T0E?oc=5","date":"2025-06-23","type":"pipeline","source":"Stock Titan","summary":"Phathom Pharmaceuticals Strengthens Leadership: Sage Therapeutics Legal Head Joins GI-focused Biotech as CLO - Stock Titan","headline":"Phathom Pharmaceuticals Strengthens Leadership: Sage Therapeutics Legal Head Joins GI-focused Biotech as CLO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNYWJLSHNQeTR5c3FvWDNWbTVKRlplZ0Y2ODZCV1d6YzRHNGdGRzRwMXpnQVhFNDdrT3gySnFIRzZEV1c2TEJEM0VXYmFTbTBpMmVaaGhTUlc5Y2xPNWtIdFgteEJFaEpNaUJlVzVuX19OdEQyZzFRdXpGTFBUM1NvaDZJZmRSUnRsLUx1NWhRWnJoc2xqYkRwU0FMWFYtM0owc3FPTmx4X1NsWDhqcEtWRFd2eU9pLUViTXlZQ2VKTQ?oc=5","date":"2024-03-20","type":"pipeline","source":"Reuters","summary":"Ex-Aegerion drug salesman avoids further prison during 2nd sentencing - Reuters","headline":"Ex-Aegerion drug salesman avoids further prison during 2nd sentencing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOdERQclhBS29FMXhoTHpCWjZuVWNrNWFfbXpMSW9GQkNMWlpsZnBDeXgtRFZ2MnBoeEFCdnZmd0dEc3dTb1VUWUJjbDZiV2Z2c00xdDU3TXpSeUE0M0FMZWp6MlVzZEtzT1h6RjMzZFJxNVpKNWNTdDVqQlBacFJrdkR0QVlxMm1RWXRDamdNYi1CdW1PZzlVX0FYWGJYckZQdmc?oc=5","date":"2019-09-25","type":"deal","source":"Fierce Biotech","summary":"Amryt buys Aegerion via bankruptcy, adding sales to support R&D - Fierce Biotech","headline":"Amryt buys Aegerion via bankruptcy, adding sales to support R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQd0ZKU05TUzhhNmR6Y3RDS19tSG1nOW5mSjRNN1IyR0s5eGlXdDhZQU5xV1ZZTE44ZXQ2NUlwWnQ3ME43M25vNHhvX200bkVQNkJwcTJ1S1pIYVE3ejFSWnViY2ZpVnp4TVFOcUl1WXViRFhFSzdBT3REZl8zbG9XREs0SXYzd0hnVEtTRkRHOFRPeFpvY0E?oc=5","date":"2019-09-11","type":"pipeline","source":"WSJ","summary":"Judge Clears Amryt Pharma’s Acquisition of Aegerion - WSJ","headline":"Judge Clears Amryt Pharma’s Acquisition of Aegerion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOd2FOSWppeW5oTFkzUl9qcks4dUZOdk02MTBJaVhHalhscmZuY25kNU9saVZrendiam9fTUVvb2oyazhKRVRvSm5QdnVMQlZFOWUtU190THBpSlpRdjctUUlObDRsanhyZ2k0UjJyaGNheVVtdEFGU01KUjlvSnAwaDl3QXRxalluYVhlcnBxONIBVkFVX3lxTFBXMEpWaVJYQlJLeUZKcGdXVENLSzEzWDB4RUhwVDZ6VFk0MHBSNXBzRVhEQnpKMUJmcVY4NUJ1eUVEQ2hraXczcGhrYnZ2N1pyLWRyQTFB?oc=5","date":"2019-08-22","type":"pipeline","source":"Law360","summary":"Aegerion Pharma's Ex-CEO Objects To Ch. 11 Plan - Law360","headline":"Aegerion Pharma's Ex-CEO Objects To Ch. 11 Plan - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOa3dDZGluanVMMGxucDl1SERuVkg3YS1QR3VyMEE2X21qVDh2MUx3NFNmV1NfOFozOUgycHNlM2hrZld2dzFDVlhpSGJiTXBfeU93NGI4d1FfX0IwdW1BUFFWWHFFOUE3cE1tRXdORF9qbkNpTE5wM1RGbkh6R3BpTUFHUDFUa3k3MjhXUEJn?oc=5","date":"2019-05-21","type":"deal","source":"BioSpace","summary":"Amryt Acquires Aegerion to Expand its Rare Disease Portfolio - BioSpace","headline":"Amryt Acquires Aegerion to Expand its Rare Disease Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQOEI1N0lDcjRCbE01a3NUUE5pMnpzc2tDRlg4YnRmQktzTmdNYmkyZXk4MjVWUU1kZHI3WDdpbWhVRTVKalNGdVhwNkJaTGZrNkhDTU0xci1FQ1EwV0wtU216aG9kaGlZMU1sM1lCTmRIbmdMeW1Od1dyVXZmVlZEY0pSaFNLTno1N1FHdzVpN1lVNVFrZG9KeGFn?oc=5","date":"2019-05-21","type":"deal","source":"pharmaphorum","summary":"Amryt to expand rare disease portfolio with $311m Aegerion merger - pharmaphorum","headline":"Amryt to expand rare disease portfolio with $311m Aegerion merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AJBVV95cUxNTWhOdEZoTy1URkkyVU9WbDY1aWJXVkw4VHFObWhwRERPSUdPd2g5ZG1ZczM1N2dHWjliZ19mZFk2cXdIQlA1T2xHN0NOM1pSV1d6RXpxMC05dzhRQnFuUHBOWU5ZbDZuUnZnOXpFQllScEE1TGdFYkJwSGprYWV0OHl1R1oyMXRZQjY3a1VVeHRHQ2lINFEwaXpLWExSZTlkUUxBRFhZaTdoOTM5OE1UVkhtZXhyM2pfN3c4X1NoMExKdnRDejVxQWYteEN6Yzg3WjdxeExzc29vaHU2b3hZTklvb0YxYkNMNkw2ZHhFTUNKUDVPUFRXNlMxQS05UUFadnVXcXF0V294VXYtYWdXazRmQnYwdGtPYmgwU1JtWFluTkdrWjZrbDJCSTBDdGFHWFhPQk5YZzhWNUo5ZGNfc29zb29BaE5CWU1qZUdLZFZHNUtoMi1FbC1lTXZHbUJyeUwzTUpmRXhRaFVF?oc=5","date":"2019-05-20","type":"pipeline","source":"GlobeNewswire","summary":"Novelion Therapeutics Announces Subsidiary Aegerion - GlobeNewswire","headline":"Novelion Therapeutics Announces Subsidiary Aegerion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPSmFOUk5nUk5EZHZsTnM0dG4zTW5IWlhVZVY3aTdNaVRWSTRpUHVpejl4djhJdzlpTTZSOGVnTWNLWFluTzZybkRSVDBMOXBaYWtTUVB5WVRvMzZaOUdxczdvb1pTRDljSDNUcEF4dmpYVXV3dWJzb1hCYkdDVXF1REZ3NA?oc=5","date":"2018-06-27","type":"regulatory","source":"Medtruth","summary":"FDA Reveals Pharma Companies Blocking Cheaper Generic Medications - Medtruth","headline":"FDA Reveals Pharma Companies Blocking Cheaper Generic Medications","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNMXZMWExuVlNSYTcwZ3NFV0NRcEtNOThIdFhDTFpRRmI5aHdqejN1YnhPUW1OY05jaHBsN2ZnZ3Jndkl6aFo1RDhLZ1dFRko3X1BaYTBKbVZKZ3d2Zm5LMlhNZHJLTGhCMGE5YXRVbGNJRTJ6b3NQTUVVb2JaRW1hZVF0WWZNTVdRZkVkbXRwdC05LTZRSnRhZjczenVnNDJhZXc?oc=5","date":"2018-03-09","type":"pipeline","source":"PMLiVE","summary":"Amryt Pharma appoints Jordi Casals as head of Europe - PMLiVE","headline":"Amryt Pharma appoints Jordi Casals as head of Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOelBoT3R0Ym1FaFlmU1Z4akFXazY0aVJ6Zzk0RkRSUkhQM0tYOXZDQ3h6YWdYZDlkSVV1ZDhkdU5TcU5zV1pwS3ZERXdXdWJRNkV0bHlXNk9BQnNpeFFmSUZpSmZ5UGNvM2czQUJjZ2k4NnpzWUVQbzdOTlQ5T1BfR0E4NG92VEkxRDVkamdsOTJ2VVNYRnh3QUNiNXdaQW5uVW1KYnNPX1NWUXBSa05hd0J0ODREc1F6SFE?oc=5","date":"2018-01-31","type":"regulatory","source":"Fierce Pharma","summary":"Judge that nixed Juxtapid's DOJ settlement prompts Aegerion to admit its off-label sins - Fierce Pharma","headline":"Judge that nixed Juxtapid's DOJ settlement prompts Aegerion to admit its off-label sins","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOSS1acFRycUw5b29lNzY2YVkwdnhBTHZZQkN5a29UVDVTWDZ0c0s5Q2dKOGlfX2xlYmhkWEJlaW9lRm1lVTFMc0ZpcHZiZDI4cU9JLUJwN1hXekJuTG9OTW1XZVVEZ05FMW03MGd4ZjUxb2k1LTZNb3k1QzhjX19oSzc4ODZ2alpoMXNuOS11MVFocTNEUlliZ1pjTV9ZYTFWSHFURm5GM04tMHlqalVLVjlmQmphQnM?oc=5","date":"2016-06-15","type":"pipeline","source":"BioPharma Dive","summary":"Facing legal troubles and declining sales, Aegerion to merge with Canadian QLT - BioPharma Dive","headline":"Facing legal troubles and declining sales, Aegerion to merge with Canadian QLT","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":3,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}